AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes ...

Meanwhile, AZ is working to expand Fasenra, Tezspire and IL-33 candidate tozorakimab into COPD. The company believes there is value in bringing multiple biologics to the indication. “Sometimes ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...

AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...